Actavis Extends ATP World Tour Finals Partnership

Global pharmaceutical company Actavis has renewed its partnership with the Barclays ATP World Tour Finals for two more years.

Actavis will once again hold a strong courtside presence at The O2 in London where the Top 8 players in the world battle it out to claim the coveted trophy at the year-end climax to the men’s professional tennis season.

The partnership is designed to raise the global awareness of the Actavis brand.

“Our 2013 partnership was a great success. The Barclays ATP World Tour Finals enjoyed a record global TV audience and we are convinced that the tennis season finale, with its impressive roster of stars, provides an excellent platform for presenting our brand identity to viewers around the world and the spectators at the tournament,” said Lars Ramneborn, Actavis’ Senior Vice President Pharma Division International.

“We are delighted to extend our partnership with Actavis, an industry leader in the world of pharmaceuticals,” said Laurent Delanney, Commercial Director of the ATP. “The variety and international scope of our partners continues to demonstrate the global appeal of our sport and our ability to deliver resounding value to our partners and their stakeholders.”